Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
US7744891B2 · kind B2 · utility
2Cited by
15References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 13, 2007 |
| Grant date | Jun 29, 2010 |
| Priority date | — |
| Expiry date | Sep 14, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.